MorphoSys GmbH Company Profile

00:07 EST 19th November 2017 | BioPortfolio

MorphoSys AG, located in Martinsried/Munich, is one of the world's leading biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of antibodies, which can be used to treat diseases and for research and diagnostics purposes. Numerous partnerships have already been entered into with well-known companies from the pharmaceutical and biotechnology sectors, such as Boehringer Ingelheim, Daiichi Sankyo, Merck & Co, Novartis, Pfizer, and Roche.

The Company, founded in 1992, possesses the unique HuCAL technology (the Human Combinatorial Antibody Library). This library comprises several billion different, fully human antibodies. HuCAL is a very powerful technology, which allows rapid and automated production of high-affinity antibodies. The most important feature of the library is its capability of optimizing fully human antibodies to meet predefined specifications.

Presently, MorphoSys prosecutes its business in two operating segments. One segment, the Therapeutic Antibodies unit, develops drug candidates for commercial partners as well as MorphoSys's own proprietary product pipeline. In this regard, the Company has been successful in establishing a number of partnerships with renowned biotechnology and pharmaceutical companies and also generated several proprietary therapeutic antibody candidates for out-licensing to partners. MorphoSys's second operating segment, the Research Antibodies unit, delivers high-quality antibodies to the research market, under the brand AbD Serotec. Two successful acquisitions of U.S. and U.K.-based antibody suppliers have significantly strengthened and broadened MorphoSys’s position in the research antibody market. The resulting combined activities of MorphoSys’s AbD unit serve all segments of the research and diagnostics markets.


Lena-Christ-Strasse 48


Phone: +49 (0)89 / 899 27-0
Fax: +49 (0)89 / 899 27-222

News Articles [348 Associated News Articles listed on BioPortfolio]

MorphoSys AG: MorphoSys Announces that Its Licensee, Janssen, Has Received US FDA Approval for Tremfya (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis

First Antibody Generated from MorphoSys's HuCAL Library Technology to Receive Marketing Approval PLANEGG, MUNICH, GERMANY / ACCESSWIRE / July 13, 2017 / MorphoSys AG (FSE: MOR; XETRA: MOR, Prime St...

Morphosys: Kurs bleibt unter Druck

Die Analysten von Goldman Sachs bestätigen das Rating "neutral" für die Aktien von Morphosys. Das Kursziel sehen die Experten weiter bei 55,00 Euro. Gestern gab es bei Morphosys Halbjahreszahlen. D....

Morphosys: Gegensätzliche Einstufungen

Mehrere Analystenhäuser beschäftigen sich am Freitag mit der Aktien und den Zahlen von Morphosys. So bestätigen die Experten der Deutschen Bank das Kaufrating für die Morphosys-Papiere. Das Kurszi...


Im TecDAX gelingt MorphoSys der technische Ausbruch nach oben. Möglicherweise gibt es für den MorphoSys-Antikörper Guselkumab auch eine Wirksamkeit bei psoriatischer Arthritis, einer chronisch-entz...

Morphosys: Mehrere Impulsgeber

Die Analysten von Berenberg bleiben bei der Kaufempfehlung für die Aktien von Morphosys. Das Kursziel für die Aktien von Morphosys sehen die Experten weiter bei 68,00 Euro. Derzeit läuft die Untern...

Morphosys: Ein Meilenstein in der Historie

Weitere Analysten reagieren auf die Entwicklungen bei Morphosys. So bestätigen die Experten von Berenberg die Kaufempfehlung für die Aktien von Morphosys. Das Kursziel für die Aktien sehen die Expe...

Morphosys: Enttäuschung verkraftet?

Liebe Leser, es sieht so aus, als ob sich die Morphosys-Aktie wieder gefangen hat. Denn was war das noch für eine Aufregung gewesen vor einigen Tagen, als Morphosys schlechte News gemeldet hatte un.....

MorphoSys: Super-Sprung zum Start - rein oder raus?

Wieder einmal spült eine sogenannte Meilensteinzahlung dem Biotech-Unternehmen MorphoSys (ISIN DE0006632003) Geld in die Kassen. Der MorphoSys-Lizenznehmer Janssen hat gestern die Verkaufsgenehmigu.....

PubMed Articles [15 Associated PubMed Articles listed on BioPortfolio]

Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study.

To evaluate safety (primary objective) and efficacy of increasing doses (400 U up to 800 U) of incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals GmbH) for patients with limb spasticity.

Biomechanical Characterization of Subclinical Keratoconus Without Topographic or Tomographic Abnormalities.

To present a case series of patients with subclinical keratoconus with normal topometric (anterior curvature) and tomographic findings in one eye who showed abnormalities detected by Corvis ST (Oculus...

Pulled-out locking screw re-screwed spontaneously in anterior cervical decompression and fusion with the zero-profile implant system: A case report.

The zero-profile, standalone device (Zero-P, Synthes GmbH, Switzerland) has been reported to be an effective and safe treatment method with similar clinical outcomes compared with plate. Instrumental ...

Cyclic and Torsional Fatigue Resistance of Reciprocating Single Files Manufactured by Different Nickel-titanium Alloys.

The aim of this study was to evaluate the cyclic and torsional fatigue resistance of the following reciprocating single-file systems: ProDesign R 25.06 (Easy Equipamentos Odontológicos, Belo Horizont...

Reliability of a Skin Diagnostic Device in Assessing Hydration and Erythema.

To examine the reliability of a skin diagnostic device, the SD202 (Courage+Khazaka GmBH, Cologne, Germany), in assessing hydration and erythema of periwound skin and pressure injury-prone areas.

Clinical Trials [39 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine

- Type: Bioequivalence study in male healthy volunteers, therapeutical indication (erectile disfunction) not studied - Products, dosage, and route of administration: ...

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

User Performance Evaluation of Contour® Plus One, Accu-Chek® Performa Connect, FreeStyle Optium Neo and OneTouch® Select Plus Blood Glucose Monitoring Systems Following ISO 15197:2013; EN ISO 15197:2015

The user performance evaluation shows whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system. In this study, user performance e...

Telemedical Examination of a Three-Component Oculomotor Testing Battery

The study investigates the feasibility and safety of the telemedical implementation of three diagnostic oculomotor tests using a video-oculography device and an extended teleconferencing s...

Influence of Non-invasive Neurostimulation (Transcutaneous Vagus Nerve Stimulation) on 1. the Noradrenergic Release in the Brain and 2. a Neuropsychological Memory Task

The goal of this study is to investigate the influence of transcutaneous vagus nerve stimulation 1. on the noradrenergic system in the brain and 2. on memory, in healthy volunteers. ...

Companies [528 Associated Companies listed on BioPortfolio]

MorphoSys GmbH

MorphoSys AG, located in Martinsried/Munich, is one of the world's leading biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next ge...

Biogenesis Ltd

Biogenesis is a recognized leader in the supply of monoclonal and polyclonal antibodies and custom manufacturing services to IVD manufacturers, pharmaceutical companies and life science researchers ar...

MorphoSys AG,

MorphoSys AG, located in Martinsried/Munich, is one of the world's leading biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next ge...

Chemie-Kontor GmbH

Chemie-Kontor GmbH trades with chemical specialities for customers in Pharma-, Agro-, Cosmetics and Nutrition Industries and offers a broad range of services. Chemie-Kontor GmbH is agent for: Amberger...

MorphoSys AG

MorphoSys AG, located in Martinsried/Munich, is one of the world's leading biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next ge...

More Information about "MorphoSys GmbH" on BioPortfolio

We have published hundreds of MorphoSys GmbH news stories on BioPortfolio along with dozens of MorphoSys GmbH Clinical Trials and PubMed Articles about MorphoSys GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MorphoSys GmbH Companies in our database. You can also find out about relevant MorphoSys GmbH Drugs and Medications on this site too.

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Corporate Database Quicklinks

Searches Linking to this Company Record